rs11077
|
POLR1C;XPO5
|
Liver carcinoma
|
|
0.020 |
GeneticVariation |
BEFREE |
Although we found no direct association between DICER (rs3742330 and rs13078), DROSHA (rs10719 and rs6877842), RAN (rs14035) or XPO5 (rs11077</span>) polymorphisms and HCC risk, we demonstrated that DICER (rs3742330) and RAN (rs14035) were associated with the survival of HCC patients.
|
27611467 |
2016 |
rs11077
|
POLR1C;XPO5
|
Liver carcinoma
|
|
0.020 |
GeneticVariation |
BEFREE |
This is the first study reporting that polymorphisms related to miRSNPs have prognostic value in hepatocellular carcinoma and identify the A/A genotype of rs11077 SNP site located in XPO5 3'UTR can help to predict worse prognosis in patients.
|
24676133 |
2014 |
rs11077
|
POLR1C;XPO5
|
Coronary Artery Disease
|
|
0.010 |
GeneticVariation |
BEFREE |
The aim of the study was to analyze the association between SNPs in two key genes (DICER rs1057035T>C and XPO5 rs11077A>C) and coronary artery disease (CAD) risk as well as to examine their effects on circulating levels of vascular miRNAs.
|
31185329 |
2019 |
rs11077
|
POLR1C;XPO5
|
Diabetes Mellitus, Non-Insulin-Dependent
|
|
0.010 |
GeneticVariation |
BEFREE |
<b>Methods:</b> We conducted a case-control study in genotyping of five polymorphic loci, including <i>RAN</i> rs14035, <i>XPO5</i> rs11077, <i>DICER1</i> rs13078, <i>DICER1</i> rs3742330, and <i>TARBP2</i> rs784567, in miRNA processing genes to explore the risk factors for T2DM and diabetic vascular complications.
|
31354628 |
2019 |
rs11077
|
POLR1C;XPO5
|
Venous Thromboembolism
|
|
0.010 |
GeneticVariation |
BEFREE |
We investigated the genetic association between polymorphisms in four miRNA biogenesis genes, <i>DICER1</i> rs3742330A > G, <i>DROSHA</i> rs10719T > C, <i>RAN</i> rs14035C > T and <i>XPO5</i> rs11077A > C, and VTE in 503 Koreans: 300 controls and 203 patients.
|
31374978 |
2019 |
rs11077
|
POLR1C;XPO5
|
Diabetic Angiopathies
|
|
0.010 |
GeneticVariation |
BEFREE |
<b>Methods:</b> We conducted a case-control study in genotyping of five polymorphic loci, including <i>RAN</i> rs14035, <i>XPO5</i> rs11077, <i>DICER1</i> rs13078, <i>DICER1</i> rs3742330, and <i>TARBP2</i> rs784567, in miRNA processing genes to explore the risk factors for T2DM and diabetic vascular complications.
|
31354628 |
2019 |
rs11077
|
POLR1C;XPO5
|
Squamous cell carcinoma of esophagus
|
|
0.010 |
GeneticVariation |
BEFREE |
Furthermore, the rs11077 AA genotype displayed a trend for high XPO5 expression in ESCC tissues by immunochemistry analysis, and these high XPO5 expression levels were also associated with high survival rates among ESCC patients.
|
29226993 |
2018 |
rs2257082
|
POLR1C;XPO5
|
Neoplasms
|
|
0.010 |
GeneticVariation |
BEFREE |
More patients with XPO5 rs2257082 CC genotype had poorly differentiated tumors compared with CT+TT genotype carriers.
|
29683064 |
2018 |
rs55671916
|
POLR1C;XPO5
|
Exfoliation Syndrome
|
|
0.010 |
GeneticVariation |
BEFREE |
Polymorphism rs1057035 (DICER) and rs55671916 (XPO5) in the 3'-UTR of genes related to miRNA biogenesis was associated with decreased risk of PEX [OR = 0.65, 95%CI: 0.46-0.92, p = 0.014] and increased risk of PEXG [OR = 2.84, 95%CI: 1.02-7.94, p = 0.038], respectively.
|
30148417 |
2018 |
rs11077
|
POLR1C;XPO5
|
Thyroid carcinoma
|
|
0.010 |
GeneticVariation |
BEFREE |
The results in our case-control study also confirmed that XPO5 rs11077 was significantly associated with onset of TC (GT/GG vs TT P = 0.035, adjusted odds ratio = 1.25, 95% confidence interval = 1.02-1.54).
|
28383405 |
2017 |
rs11077
|
POLR1C;XPO5
|
Thyroid Neoplasm
|
|
0.010 |
GeneticVariation |
BEFREE |
The results in our case-control study also confirmed that XPO5 rs11077 was significantly associated with onset of TC (GT/GG vs TT P = 0.035, adjusted odds ratio = 1.25, 95% confidence interval = 1.02-1.54).
|
28383405 |
2017 |
rs11077
|
POLR1C;XPO5
|
Malignant neoplasm of thyroid
|
|
0.010 |
GeneticVariation |
BEFREE |
The results in our case-control study also confirmed that XPO5 rs11077 was significantly associated with onset of TC (GT/GG vs TT P = 0.035, adjusted odds ratio = 1.25, 95% confidence interval = 1.02-1.54).
|
28383405 |
2017 |
rs11077
|
POLR1C;XPO5
|
Secondary malignant neoplasm of lymph node
|
|
0.010 |
GeneticVariation |
BEFREE |
Other clinical features were all considered to have no apparent effect in influencing the prognostic outcomes of advanced NSCLC patients receiving chemotherapy except lymph node metastasis (P < 0.05). miR-SNP rs11077 of XPO5 may be independently connected with the prognosis and chemotherapy response of advanced NSCLC patients, and patients with AC genotype have relatively improved prognostic outcomes and better curative effect of chemotherapy than those with AA allele of XPO5.
|
26358254 |
2016 |
rs11077
|
POLR1C;XPO5
|
Non-Small Cell Lung Carcinoma
|
|
0.010 |
GeneticVariation |
BEFREE |
Multivariate analysis results indicated that the SNP sites of rs11077 might be an independent prognostic factor of advanced NSCLC patients receiving chemotherapy (risk ratio [RR] = 0.346; 95 % confidence interval [95 % CI] = 0.174-0.685, P = 0.002).
|
26358254 |
2016 |
rs11077
|
POLR1C;XPO5
|
Colorectal Carcinoma
|
|
0.010 |
GeneticVariation |
BEFREE |
Furthermore, patients diagnosed with hypertension or DM who carried the DROSHA rs10719 CC genotype showed increased CRC risk, while the XPO5 rs11077 AC+CC genotype led to increased CRC risk in patients with hypertension only.
|
26147304 |
2015 |
rs11077
|
POLR1C;XPO5
|
Hypertensive disease
|
|
0.010 |
GeneticVariation |
BEFREE |
Furthermore, patients diagnosed with hypertension or DM who carried the DROSHA rs10719 CC genotype showed increased CRC risk, while the XPO5 rs11077 AC+CC genotype led to increased CRC risk in patients with hypertension only.
|
26147304 |
2015 |
rs11077
|
POLR1C;XPO5
|
Ovarian Failure, Premature
|
|
0.010 |
GeneticVariation |
BEFREE |
A haplotype-based analysis of seven polymorphisms of the microRNA machinery genes for gene-gene interactions suggests that ***ACTA, ***GCCA, ***G*C*, *T*ATTA, and ***ACT* haplotypes (asterisk indicates SNP locus not included; DROSHA rs6877842 and rs10719, DICER1 rs13078 and rs3742330, RAN rs14035, and XPO5 rs2257082 and rs11077 polymorphisms) are associated with higher POI prevalence, and that ***GCTA, ***ACCA, *C*ATTA, and *C*ATT* haplotypes are associated with lower POI prevalence.
|
23549446 |
2013 |
rs2257082
|
POLR1C;XPO5
|
Ovarian Failure, Premature
|
|
0.010 |
GeneticVariation |
BEFREE |
Our data demonstrate that the XPO5 rs2257082 T variant allele occurs more frequently in POI patients than in controls, suggesting that this allele may be associated with increased POI risk.
|
23549446 |
2013 |